DrugPatentWatch Database Preview
Incyte Corp Company Profile
What is the competitive landscape for INCYTE CORP, and when can generic versions of INCYTE CORP drugs launch?
INCYTE CORP has one approved drug.
There are six US patents protecting INCYTE CORP drugs.
There are one hundred and forty-eight patent family members on INCYTE CORP drugs in forty-one countries and twenty supplementary protection certificates in thirteen countries.
Summary for Incyte Corp
| International Patents: | 148 |
| US Patents: | 6 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Incyte Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-002 | Nov 16, 2011 | RX | Yes | No | 7,598,257 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-002 | Nov 16, 2011 | RX | Yes | No | 8,722,693 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-002 | Nov 16, 2011 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for INCYTE CORP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg | ➤ Subscribe | 2015-12-17 |
International Patents for Incyte Corp Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Poland | 2474545 | ➤ Try a Free Trial |
| Singapore | 179430 | ➤ Try a Free Trial |
| Cyprus | 1118506 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Incyte Corp Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2017 00018 | Denmark | ➤ Try a Free Trial | PRODUCT NAME: RUXOLITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER RUXOLITINIB FOSFAT; REG. NO/DATE: C(2015)1740/EU/1/12/773/001-016 20150313 |
| 2013 | Austria | ➤ Try a Free Trial | PRODUCT NAME: RUXOLITINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823 |
| C0007 | France | ➤ Try a Free Trial | PRODUCT NAME: RUXOLITINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120828 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
